Outcome of MDR-TB patients, 1983-1993 - Prolonged survival with appropriate therapy

被引:137
|
作者
Park, MM
Davis, AL
Schluger, NW
Cohen, H
Rom, WN
机构
[1] NYU,MED CTR,DEPT MED,DIV PULM & CRIT CARE MED,NEW YORK,NY
[2] NYU,MED CTR,DEPT ENVIRONM MED,NEW YORK,NY
[3] NYU,MED CTR,BELLEVUE CHEST SERV,NEW YORK,NY
关键词
D O I
10.1164/ajrccm.153.1.8542137
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
We analyzed the clinical and laboratory findings and outcome of 173 patients hospitalized at our institution from 1983 to 1994 with multidrug-resistant tuberculosis (MDR-TB) and evaluated outcome. The 173 patients (mean age 40 +/- 1 yr) were predominantly male (92%), African American or Hispanic (80%), and mostly undomiciled. Over half (52%) were known to be HIV-infected. HIV-positive MDR-TB patients had significantly more pulmonary and constitutional symptoms, more extrapulmonary disease, and fewer cavitary lesions on chest radiographs. Fifty-five percent of the patients in the cohort have died; mortality was significantly greater for HIV-positive than HIV-negative (72% versus 20%, p < 0.01). The median duration of survival of MDR-TB patients was 22 +/- 1 mo. Overall, extrapulmonary involvement was a risk factor for shorter survival, while a cavitary lesion on initial chest film and institution of appropriate treatment were positive predictors of survival. In HIV+ patients, only appropriate therapy was associated with prolonged survival (median of 14.1 mo). Interestingly, there was a trend toward better outcome in the first half of the decade reviewed. We conclude that although mortality from MDR-TB is high in both HIV-positive and HIV-negative patients, institution of appropriate therapy is the factor most strongly associated with a favorable outcome. Development of new and therapeutic strategies for MDR-TB are urgently needed.
引用
收藏
页码:317 / 324
页数:8
相关论文
共 50 条
  • [31] Genotype MTBDR (Hain) test in suspected MDR-TB patients
    Sangsayunh, Piamlarp
    Cheewakul, Krisana
    Chuchothawon, Chareon
    EUROPEAN RESPIRATORY JOURNAL, 2013, 42
  • [32] Prevalence and Factors Associated with Multidrug-Resistant Tuberculosis (MDR-TB) among Presumptive MDR-TB Patients in Tigray Region, Northern Ethiopia
    Mehari, Kibriti
    Asmelash, Tsehaye
    Hailekiros, Haftamu
    Wubayehu, Tewolde
    Godefay, Hagos
    Araya, Tadele
    Saravanan, Muthupandian
    CANADIAN JOURNAL OF INFECTIOUS DISEASES & MEDICAL MICROBIOLOGY, 2019, 2019
  • [33] Recombinant adenovirus expressing granulysin is an effective adjunctive therapy for MDR-TB
    Hao, L.
    Ma, J.
    Shi, C.
    Fan, X.
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2019, 49 : 1688 - 1688
  • [34] Thioridazine: evidence supporting its use as alternative therapy for MDR-TB
    Amaral, L
    Ordway, D
    Viveiros, M
    Martins, M
    Leandro, C
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2004, 24 : S169 - S169
  • [35] The Impact of Concurrent Antiretroviral Therapy and MDR-TB Treatment on Adverse Events
    Smith, Jonathan P.
    Gandhi, Neel R.
    Shah, N. Sarita
    Mlisana, Koleka
    Moodley, Pravi
    Johnson, Brent A.
    Allana, Salim
    Campbell, Angela
    Nelson, Kristin N.
    Master, Iqbal
    Brust, James C. M.
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2020, 83 (01) : 47 - 55
  • [36] Long Term Treatment Outcome in Multi Drug Resistant Tuberculosis (MDR-TB)
    Prasad, R.
    Verma, S. K.
    Verma, S. K.
    Jain, A.
    Ahuja, R. C.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2009, 179
  • [37] Specific gyrA gene mutations predict poor treatment outcome in MDR-TB
    Rigouts, L.
    Coeck, N.
    Gumusboga, M.
    de Rijk, W. B.
    Aung, K. J. M.
    Hossain, M. A.
    Fissette, K.
    Rieder, H. L.
    Meehan, C. J.
    de Jong, B. C.
    Van Deun, A.
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2016, 71 (02) : 314 - 323
  • [38] Long term treatment outcome in multi drug resistant tuberculosts(MDR-TB)
    Prasad, R
    CHEST, 2004, 126 (04) : 836S - 836S
  • [39] Management of multidrug resistant tuberculosis (MDR-TB) - Monitoring is the key to successful outcome
    Akshata, J. S.
    Chakrabarthy, Anushree
    EGYPTIAN JOURNAL OF CHEST DISEASES AND TUBERCULOSIS, 2016, 65 (02): : 447 - 450
  • [40] Evaluate the potential of IP-10 as biomarker for the MDR-TB treatment outcome
    Huang, Yi-Wen
    Tsai, Hsin-Chieh
    Chen, Chia-Ming
    Yu, Ya-Yen
    Shen, Gwan-Han
    Yang, Wen-Ta
    EUROPEAN RESPIRATORY JOURNAL, 2013, 42